Biodexa Pharmaceuticals reported asset growth of -17.10% for the quarter ended Jun 2026. These growth metrics cover 22 quarters of results from Dec 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Dec2014 | Dec2015 | Dec2016 | Jun2017 | Dec2017 | Jun2018 | Dec2018 | Jun2019 | Dec2019 | Jun2020 | Dec2020 | Jun2021 | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Dec2023 | Jun2024 | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||||||||||||||||
| Assets Growth (1y) | -26.60% | -22.71% | -5.02% | -20.43% | -60.78% | -22.83% | 56.11% | -59.17% | -66.97% | -22.44% | 30.26% | -61.78% | 101.53% | 75.87% | 38.17% | 15.14% | 32.00% | -17.10% | ||||
| Assets Growth (3y) | 101.34% | -3.07% | -35.09% | -22.00% | -16.53% | -36.95% | -41.30% | -37.48% | -12.42% | -45.22% | -12.06% | 0.11% | 15.53% | 2.09% | 54.32% | 18.85% | ||||||
| Assets Growth (5y) | 24.91% | -11.02% | -32.42% | -31.55% | -24.20% | -36.82% | -26.52% | -12.35% | -13.36% | -14.47% | 6.61% | 12.84% | 8.04% | |||||||||
| Capital Expenditures Growth (1y)Capex Growth (1y) | ||||||||||||||||||||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -9.73% | -17.30% | -17.98% | -33.11% | -83.24% | 111.39% | 381.82% | -53.18% | -28.22% | 31.98% | -74.81% | -15.38% | 122.38% | -3.05% | -72.45% | -13.38% | 448.73% | -22.69% | ||||
| Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) | 76.47% | -27.83% | -50.12% | 5.36% | -12.83% | -12.84% | -16.63% | 65.88% | -11.86% | -37.98% | 7.36% | -9.58% | -46.37% | -10.76% | 49.80% | -13.41% | ||||||
| Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) | -5.46% | -21.22% | -15.57% | -8.90% | -0.64% | -28.06% | 4.14% | 20.65% | -10.89% | -31.93% | 0.77% | 2.24% | ||||||||||
| Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) | ||||||||||||||||||||||
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | ||||||||||||||||||||||
| EBIT Growth (1y) | 106.22% | 4.28% | -109.07% | |||||||||||||||||||
| EBIT Growth (3y) | 33.81% | 31.07% | -91.68% | 32.72% | ||||||||||||||||||
| EBIT Growth (5y) | -15.85% | 1.06% | 8.10% | |||||||||||||||||||
| EBT Growth (1y) | 106.48% | 11.98% | -120.67% | |||||||||||||||||||
| EBT Growth (3y) | 33.23% | 28.95% | -90.07% | 34.28% | ||||||||||||||||||
| EBT Growth (5y) | -15.08% | 2.07% | 6.98% | |||||||||||||||||||
| EPS (Basic) Growth (1y) | 101.83% | 73.61% | -383.43% | -19.24% | ||||||||||||||||||
| EPS (Basic) Growth (3y) | 0.41% | -153.05% | 36.44% | 88.79% | ||||||||||||||||||
| EPS (Basic) Growth (5y) | -4.73% | 80.22% | 85.05% | |||||||||||||||||||
| Free Cash Flow Growth (1y)FCF Growth (1y) | ||||||||||||||||||||||
| Gross Profit Growth (1y) | -82.91% | -63.19% | ||||||||||||||||||||
| Gross Profit Growth (3y) | -99.36% | -99.18% | ||||||||||||||||||||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | -479.70% | 54.19% | ||||||||||||||||||||
| Interest Coverage Ratio Growth (3y)Interest Cover Growth (3y) | 63.65% | -10.50% | ||||||||||||||||||||
| Interest Coverage Ratio Growth (5y)Interest Cover Growth (5y) | -11.49% | -14.16% | 33.75% | |||||||||||||||||||
| Net Cash Flow Growth (1y)NCF Growth (1y) | ||||||||||||||||||||||
| Net Income Growth (1y) | -63.56% | 32.96% | -125.96% | |||||||||||||||||||
| Net Income Growth (3y) | -46.91% | -8.06% | 19.72% | 30.35% | ||||||||||||||||||
| Net Income Growth (5y) | -19.59% | 1.49% | -13.84% | |||||||||||||||||||
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | 102.34% | 32.96% | -125.96% | -19.24% | ||||||||||||||||||
| Net Income towards Common Stockholders Growth (3y)Net Income Growth (3y) | 27.12% | -8.06% | -236.46% | 34.82% | -12.14% | |||||||||||||||||
| Net Income towards Common Stockholders Growth (5y)Net Income Growth (5y) | -23.94% | 1.49% | -13.84% | 20.01% | 29.61% | |||||||||||||||||
| Operating Income Growth (1y)Op. Inc Growth (1y) | 106.22% | 4.28% | -109.07% | |||||||||||||||||||
| Operating Income Growth (3y)Op. Inc Growth (3y) | 33.81% | 31.07% | -91.68% | 32.72% | ||||||||||||||||||
| Operating Income Growth (5y)Op. Inc Growth (5y) | -15.85% | 1.06% | 8.10% | |||||||||||||||||||
| Profit After Tax Growth (1y)PAT Growth (1y) | 100.81% | 11.98% | -132.72% | |||||||||||||||||||
| Profit After Tax Growth (3y)PAT Growth (3y) | 26.94% | 28.95% | -245.07% | 32.18% | ||||||||||||||||||
| Profit After Tax Growth (5y)PAT Growth (5y) | -15.08% | 2.07% | 5.98% | |||||||||||||||||||
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | 15.60% | 6.76% | 0.01% | -7.13% | -25.95% | -32.66% | 12.21% | -47.09% | -73.84% | 47.10% | 110.48% | -35.57% | -27.43% | -36.93% | -44.08% | -53.47% | -69.86% | -89.67% | ||||
| Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) | 44.42% | 12.93% | -5.05% | -12.60% | -5.98% | -30.83% | -39.88% | -19.37% | -14.83% | -29.21% | -9.37% | -0.53% | -31.66% | -36.05% | -50.36% | -68.82% | ||||||
| Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) | 17.41% | 3.66% | -24.14% | -12.27% | -14.48% | -21.68% | -23.31% | -21.99% | -24.31% | -32.14% | -26.23% | -30.18% | -56.63% | |||||||||
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | 0.00M | -0.03M | ||||||||||||||||||||
| Return on Assets [ROA] Growth (3y)ROA Growth (3y) | -0.01M | |||||||||||||||||||||
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | 0.00M | -0.03M | ||||||||||||||||||||
| Return on Capital Employed [ROCE] Growth (3y)ROCE Growth (3y) | -0.01M | |||||||||||||||||||||
| Return on Equity [ROE] Growth (1y)ROE Growth (1y) | 0.00M | -0.06M | ||||||||||||||||||||
| Return on Equity [ROE] Growth (3y)ROE Growth (3y) | -0.01M | -0.08M | ||||||||||||||||||||
| Revenue Growth (1y) | -114.96% | |||||||||||||||||||||
| Total Debt Growth (1y) | -8.24% | -4.66% | 231.79% | 278.03% | -81.94% | -84.12% | 401.84% | 211.38% | -95.56% | -73.97% | 191.76% | -81.98% | -27.24% | 238.71% | -21.46% | -29.61% | 54.41% | 42.29% | -91.00% | |||
| Total Debt Growth (3y) | -21.84% | 41.87% | -18.07% | -16.98% | 44.35% | 23.18% | -65.72% | -49.51% | -13.35% | -47.33% | -54.48% | -45.84% | 18.58% | -24.54% | -4.09% | 50.26% | -52.20% | |||||
| Total Debt Growth (5y) | -22.14% | 20.95% | -34.28% | -14.25% | -17.17% | -38.54% | -38.85% | -39.88% | -17.95% | -19.02% | -35.18% | -30.76% | -25.35% |
Pull Biodexa Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=BDRX&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "BDRX", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=BDRX&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();